Compare 8x8 Inc (EGHT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs BIO-TECHNE Corp — how do they compare? 8x8 Inc trades at $2.2 (market cap $307.65M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 37× 8x8 Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and BIO-TECHNE Corp for 63 Days on average.
| EGHT | TECH | |
|---|---|---|
Market Cap | $307.65M | $11.37B |
Volume | 750,629 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $2.76 | $72.61 |
52-Week Low | $1.59 | $43.31 |
Typical Hold Time | 16 Days | 63 Days |
Enterprise Value | $574.57M | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.14, down 1.38% today, with a bullish technical signal from moving averages and strong momentum indicators. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client implementations and AI product growth, while analyst consensus targets $19.77 with mixed ratings.
The outlook suggests potential upside if profitability materializes as projected, supported by operational efficiency gains and AI adoption. Key risks include high debt levels, negative cash flow, and competitive pressures in the communications software sector that could challenge margin expansion.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
